The article reviews the recent advances in haemodialysis technology and their relevance to current clinical practice.
In-centre haemodialysis (HD) has become the predominant renal replacement therapy in many parts of the world, and in many Asian countries, such as Philippines, Japan and Taiwan, 1 more than 80% of the end-stage renal disease (ESRD) population were being treated with this modality. Despite its widespread utilization, many clinicians had suggested that HD may confer several disadvantages when compared to peritoneal dialysis (PD). For example, several population-based studies have demonstrated an early survival advantage in patients treated with PD over HD, [2] [3] [4] [5] with the likely reason being ascribed to its ability to preserve residual renal function. 6 Indeed, in both the NECOSAD 7 and ADEMEX 8 studies, residual renal function was consistently noted to be an independent risk factor for patient survival in both the HD and PD population, respectively. In addition, because of the extracorporeal nature of HD, there is a higher risk of transmission of blood-borne infections and this had been reflected in the greater incidence of hepatitis B and C seroconversion in HD centres over the PD population. 9 In addition, the incidence of anaemia and dose requirements for erythropoietin-stimulating agents appeared to be higher in patients undergoing HD. 10 Other purported drawbacks of HD included lower indices in the quality-oflife assessment, 11 worse outcomes with renal transplantation 2 and higher costs to both patients and health-care system.
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Notwithstanding these issues, HD and PD should be viewed as complementary therapies rather than competing modalities. This was nicely articulated by Gokal, that by harnessing the early advantages of PD as an initial therapy and advocating the timely switch to HD, the outcomes of the ESRD patients could be optimized throughout their dialysis vintage. 13 Moreover, all these studies were done using the traditional thrice-weekly, in-centre HD treatment as a comparison. Advancement in HD technologies have, therefore, sought to overcome some of these shortfalls associated with conventional HD treatment, and these issues may, in future, not be perceived to be disadvantageous to the use of HD in the management of ESRD patients. However, before considering these new technologies for prime-time use, it is important to review the existing evidence in relation to crucial clinical outcomes, deliberate on their adverse effects and assess their cost-effectiveness over existing therapies. This article will look at three main advancement in HD treatment in the recent years -frequent HD, haemodiafiltration (HDF) and the use of novel dialyzer membranes -and provide the perspective in advocating for their clinical utility.
FREQUENT HAEMODIALYSIS
It has been suggested that dialysis time could be more important than the dialysis dose in removing middle molecules or any other solutes that traditionally are difficult to dialyze out by standard HD prescriptions. In addition, observational studies had suggested that longer dialysis times were associated with better phosphate balance and perhaps even improved mortality outcomes with dialysis duration. Eloot et al. demonstrated that by increasing dialysis time from 4 to 8 h, total solute removal, total cleared volume and dialyzer extraction ratios were significantly increased for urea, creatinine, phosphorus and β 2 -microglobulin. 14 Moreover, the DOPPS study noted that in Europe and Japan, where patients received significantly longer dialysis treatment time, dialysis duration greater than 240 min was associated with a lower relative risk of death (relative risk = 0.81; P = 0.0005), with every 30 minutes longer on HD resulting in a 7% reduction in mortality. 15 These studies prompted the consideration that more intensive HD, in the form of either short daily (SDHD) or slow nocturnal HD (NHD), may have more beneficial effects than intermittent HD. Consequently, the Frequent Hemodialysis Network (FHN) Trial Group conducted two randomized controlled trials (RCT) to investigate the effect of dialysis time on outcomes -the FHN Daily Trial investigating six times per week of HD, 16 and the FHN Nocturnal Trial looking at nocturnal home HD six times per week, 17 with both studies using conventional three times per week HD as a control group. The FHN Daily Trial was a multicentre study conducted in North America, and randomized more than 200 patients in roughly 1:1 ratio to either continue thrice-weekly HD with a minimum target equilibrated Kt/V urea of 1.1 and a session length of 2.5-4 h, or to more frequent HD six times per week with target equilibrated Kt/Vn of 0.9 and a session length between 1.5-2.75 h. The trial had two co-primary composite outcomes, which were death or change in left ventricular mass assessed by cardiac magnetic resonance imaging, and death or change in the physical-health composite score of the RAND 36-item health survey, through a follow-up period of 12 months. Both groups showed a significant separation of the delivered number of HD sessions per week (2.9 vs 5.2 treatments) and a total weekly delivered standard Kt/V urea (2.57 in the thrice-weekly group vs 3.60 in the frequent daily group). In terms of outcomes, the study demonstrated that the frequent daily HD group managed to achieve better control of hypertension and hyperphosphatemia, and attained significantly greater benefits in both co-primary composite outcomes, with a hazard ratio for death or increase in left ventricular mass of 0.61 (95% confidence interval [CI] 0.46-0.82) and a hazard ratio for death or a decrease in the physical-health composite score of 0.70 (95% CI 0.53-0.92). In addition, when the authors analyzed the long-term outcomes of the daily trial over a median follow-up period of 3.6 years, 18 the patients randomized to the frequent daily group was noted to have a lower risk of mortality compared to those in the control arm (hazard ratio 0.54, 95% CI 0.31-0.93), suggesting a significant survival benefit and low probability of harm with frequent daily HD. The FHN nocturnal trial was a smaller study with similar pre-determined co-primary outcomes to the FHN daily trial. The group randomized 87 patients, with 45 patients in the frequent nocturnal arm and 42 patients in the conventional arm. Akin to the FHN daily trial, there was a clear separation with regards to the HD prescription between the groups, with the frequent nocturnal arm having a 1.82-fold higher weekly standard Kt/V urea , a 1.74-fold higher average number of treatments per week and a 2.45-fold higher average weekly treatment time. However, unlike the FHN daily trial, the FHN nocturnal study did not demonstrate a significantly beneficial effect of frequent NHD on either of the two co-primary outcomes, although blood pressure and phosphate control appeared to be superior in the frequent nocturnal arm compared to the conventional prescription. Conversely, the longer-term mortality outcomes of the FHN nocturnal study appeared to be in contradiction to those in the FHN Daily Trial. 19 With a median follow-up period of 3.7 years, the patients in the nocturnal arm were at a higher risk of mortality with a hazard ratio of 3.88 (95% CI 1.27-11.79) and this effect was seen even when an astreated analysis was performed (HR 3.06, 95% CI 1.11-8.43).
The immediate and long-term outcomes of these two trials raised several issues that needed to be addressed. First, frequent HD does not appear to be as innocuous as originally perceived, and perhaps increasing the duration of HD is not without harm as seen in the FHN nocturnal trial. While the authors cautioned that the higher mortality rate with the frequent nocturnal group in the long term needed to be interpreted judiciously in view of the unusually low mortality rate for patients assigned to the conventional group, this is not an uncommon occurrence in many Asian countries such as Japan, where age-standardized mortality rate on HD could be as low as 97.0 per 1000 patient-years. 20 In addition, the FHN daily trial also demonstrated that frequent HD was associated with the need to undergo interventions related to vascular access, especially in the analysis of the time to the first intervention (HR 1.71, 95% CI 1.08-2.73). There was also a trend, though not statistically significant because of the small sample size, towards increased vascular access events in the nocturnal arm of the FHN nocturnal trial, which raised the concerns of vascular access dysfunction as a trade-off for more frequent HD. Consequently, the question now arises as to how frequent is considered optimal and to what extent does it become detrimental?
Notwithstanding the possible clinical benefits, the cost of frequent HD remains an unanswered issue and cost-utility analysis in this regards is sorely lacking. The infrastructure and health-care resources needed to support frequent HD are neither widely available nor practical in many low resource countries and may come at a greater expense of reduced access to renal replacement therapy to other ESRD patients. Therefore, until the optimal dialysis duration and dosing have been determined to demonstrate costeffectiveness in supporting more intensive treatment, frequent HD should not become a main-stream therapy in many countries.
HAEMODIAFILTRATION
Haemodiafiltration utilizes high volumes of substitution fluid to maximize convective therapies, and is an attractive option for the removal of large solutes that are usually poorly removed by the traditional diffusive technology of HD. Indeed, observational studies suggested that HDF may offer clinical benefits over conventional HD, including superior survival advantage. The RISCAVID study 21 looked at 757 Italian patients undergoing dialysis over a 30-month follow-up period, and found that patients undergoing HDF had lower all-cause mortality rates than standard HD, even after adjustment for multiple factors. This was consistent with the findings of the DOPPS study, 22 where compared to low-flux HD, patients receiving high-efficiency HDF had a significant 35% lower mortality risk, though this survival advantage was not seen with the group receiving lowefficiency HDF. In addition, it had been suggested that online HDF may be associated with less intradialytic hypotension, better blood pressure control, improved anaemia correction, reduced incidence of dialysis-related amyloidosis and hospitalization, 23 although these benefits were not evaluated systematically in an RCT. Three large RCT had been conducted to evaluate the benefits of HDF over conventional HD, [24] [25] [26] but unfortunately with conflicting results. The CONTRAST study 24 recruited patients from three main countries (the Netherlands, Canada and Norway) and randomized 714 chronic HD patients roughly equally to either online post-dilution HDF or to continue with low-flux HD. With a mean follow-up period of 3 years, there was no significant difference in terms of all-cause mortality or cardiovascular events between the two groups. In fact, a post-hoc analysis looking at cardiovascular parameters did not show any benefits of online HDF on changes in left ventricular mass, ventricular ejection fraction or high pulse-wave velocity over low-flux HD. 27 Similar outcomes were noted in the Turkish OL-HDF study, 25 with 782 patients randomized to either postdilution online HDF or high-flux HD. Likewise, the composite primary outcome of all-cause mortality and nonfatal cardiovascular event rate were not different between the two treatment groups, although a post-hoc analysis suggested that better outcomes were more likely in the HDF group if the substitution volumes were over 17.4 L. The ESHOL study group with the largest study population of 906 patients, on the other hand, found superior outcomes with online HDF over conventional HD therapies with about 92% being treated with high-flux membranes. 26 Not only was HDF associated with lower risk of all-cause mortality, reduced cardiovascular and infection-related deaths, it also resulted in lower incidences of intradialytic hypotension and hospitalization rates. Yet, these morbidity outcomes were in contradiction to a more recent albeit smaller randomized trial of 100 patients, comparing high-flux HD and online HDF. The authors found significantly increased rates of symptomatic hypotension, intradialytic tendency to clotting and lower serum albumin levels with the use of HDF.
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There was also no benefit of HDF over HD in terms of health-related quality of life scores. 28 These conflicting results suggested that the purported benefits of HDF are inconsistent and debatable. More importantly, whether HDF could result in more adverse outcomes and higher morbidities would require further study and should be taken as a strong clinical concern when prescribing this therapy in the current setting. It is also likely that with the higher cost ascribed with HDF treatment and the enhanced technology and expertise required in the delivery of this prescription (specialized machines, need for ultrapure water, substitution fluid and greater clinical monitoring), it is likely that this treatment may not be available in many centres. Together with the unreliable evidence for benefit, advocating for the widespread implementation of HDF in the care for ESRD patients will be extremely challenging.
MEDIUM CUT-OFF MEMBRANES
In the same respect, the development of a novel dialyzer membrane with enhanced permeability and selectivity termed medium cut-off (MCO) membrane, offers an attractive option of increasing the removal of middle-sized uremic toxins. MCO membranes had been touted to having permeability closest to that of the natural kidney, 29 with in vitro data suggesting that they allow for removal of an expanded range of larger uremic toxins when compared to high-flux membranes. In contrast to high cut-off membranes, MCO membrane could ensure the retention of albumin during HD treatment and theoretically does not have the down-side of hypoalbuminemia with long-term use.
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A short-term randomized crossover trial in 48 patients comparing HD using MCO membranes versus high-flux dialyzers over a treatment period of 4 weeks was conducted to evaluate the in vivo effects of these novel dialyzers. 30 The authors demonstrated that with the use of MCO membranes, mRNA expression of inflammatory biomarkers like tumour necrosis factor-α (TNF-α) and interleukin-6 (IL-6) in blood leukocytes were lowered to a greater extent than high-flux dialyzers. However, while albumin loss was more limited compared to previous trials using high cut-off membranes, there was still a significant reduction in serum albumin after 4 weeks of treatment with MCO membranes, although the levels stabilized at the end of another 8 weeks of treatment. Nonetheless, the extent of albumin loss with MCO membranes cannot be neglected in view of the negative impact with malnutrition, and its effect on long-term outcomes require further evaluation. Similar results were noted in another randomized crossover trial comparing MCO membranes with high-flux dialysis and HDF in consecutive studies, 31 where lambda free light chain clearance was used as the primary study outcome. Clearance of lambda free light chains was found to be superior with the MCO membranes in comparison with both high-flux dialysis and HDF, but albumin loss was again noted to be greater. While the in vivo results appeared to be promising in circumventing the inflammatory milieu associated with longterm dialysis, the authors admittedly acknowledged that their study focused mainly on surrogate parameters, and no conclusions should be drawn on the effect of MCO membranes on long-term clinical endpoints. Indeed, there are currently neither studies that had demonstrated the survival benefits with the use of MCO membranes, nor evaluated the long-term outcomes and adverse effects with the use of these novel dialyzers. Inadvertently, the cost of MCO membranes is higher than the conventional dialyzers used for HD. Without any benefits of long-term clinical endpoints, and the lack of clarity of the appropriate indication for use, it would be difficult to justify the utility of MCO membranes as a standard of care in clinical practice.
CONCLUSION
Haemodialysis had become a predominant mode of renal replacement therapy in many parts of the world, and should be considered as a complementary treatment in an integrated ESRD care programme, so as to maximize the outcomes of patients with advanced chronic kidney disease. While advancements in HD therapies have occurred over the last few years, these novel prescriptions or enhanced technologies have yet to demonstrate indisputable clinical benefits, or cost-effectiveness. It is, therefore, difficult to justify for their widespread utility across heterogeneous clinical settings or population groups, and patient selection for their use remains at the discretion of the clinician.
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